ArticleOncoTargets and therapy2022

Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.

Kan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.